Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

Mostrar outras versões (2)

Detalhes bibliográficos
Principais autores:	Haldar, P, Brightling, C, Singapuri, A, Hargadon, B, Gupta, S, Monteiro, W, Bradding, P, Green, R, Wardlaw, A, Ortega, H, Pavord, I
Formato:	Journal article
Idioma:	English
Publicado em:	2014

Registros relacionados

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
por: Haldar, P, et al.
Publicado em: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
por: Haldar, P, et al.
Publicado em: (2014)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
por: Haldar, P, et al.
Publicado em: (2009)

Mepolizumab in refractory eosinophilic asthma.
por: Pavord, I, et al.
Publicado em: (2010)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
por: Shrimanker, R, et al.
Publicado em: (2017)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
por: Shrimanker, R, et al.
Publicado em: (2017)

Exacerbations of severe asthma in patients treated with mepolizumab
por: Shrimanker, R, et al.
Publicado em: (2018)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
por: Yancey, S, et al.
Publicado em: (2016)

Glucocorticoids and mepolizumab in eosinophilic asthma.
por: Bel, E, et al.
Publicado em: (2014)

Mepolizumab treatment in patients with severe eosinophilic asthma.
por: Ortega, H, et al.
Publicado em: (2014)

Mepolizumab, quality of life, and severe eosinophilic asthma.
por: Pavord, I
Publicado em: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
por: Ortega, H, et al.
Publicado em: (2016)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
por: Bel, E, et al.
Publicado em: (2014)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
por: Gunsoy, N, et al.
Publicado em: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
por: Moran, AM, et al.
Publicado em: (2020)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
por: Howell, I, et al.
Publicado em: (2024)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
por: Pavord, I, et al.
Publicado em: (2012)

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
por: Brightling, C, et al.
Publicado em: (2003)

Mepolizumab for eosinophilic COPD
por: Sciurba, F, et al.
Publicado em: (2018)

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
por: Green, R, et al.
Publicado em: (2002)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
por: Moran, A, et al.
Publicado em: (2020)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
por: Shrimanker, R, et al.
Publicado em: (2018)

Biomarkers for severe eosinophilic asthma.
por: Yancey, S, et al.
Publicado em: (2017)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
por: Berry, M, et al.
Publicado em: (2007)

Non-eosinophilic corticosteroid unresponsive asthma.
por: Pavord, I, et al.
Publicado em: (1999)

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.
por: Bilocca, D, et al.
Publicado em: (2017)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
por: Kulkarni, N, et al.
Publicado em: (2010)

The significance of eosinophilic airway inflammation in asthma
por: Pavord, I, et al.
Publicado em: (2002)

Eosinophils in asthma and other allergic diseases.
por: Wardlaw, A, et al.
Publicado em: (2000)

Eosinophils in asthma and airway hyperresponsiveness.
por: Brightling, C, et al.
Publicado em: (2004)

Qualitative analysis of high-resolution CT scans in severe asthma.
por: Gupta, S, et al.
Publicado em: (2009)

Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis.
por: Siddiqui, S, et al.
Publicado em: (2007)

TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis.
por: Brightling, C, et al.
Publicado em: (2002)

Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes.
por: Gupta, S, et al.
Publicado em: (2010)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
por: Wechsler, M, et al.
Publicado em: (2017)

Body mass and fat mass in refractory asthma: an observational 1 year follow-up study.
por: Bafadhel, M, et al.
Publicado em: (2010)

Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis.
por: Berry, M, et al.
Publicado em: (2004)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
por: Pavord, I, et al.
Publicado em: (2017)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma.
por: Brightling, C, et al.
Publicado em: (2000)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma
por: Brightling, C, et al.
Publicado em: (2000)